Driehaus Capital Management LLC Sells 563,545 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA)

Driehaus Capital Management LLC decreased its holdings in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 26.1% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,598,183 shares of the company's stock after selling 563,545 shares during the quarter. Driehaus Capital Management LLC owned about 1.21% of Centessa Pharmaceuticals worth $26,770,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Price T Rowe Associates Inc. MD increased its stake in shares of Centessa Pharmaceuticals by 14.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,364,392 shares of the company's stock valued at $89,854,000 after acquiring an additional 685,371 shares during the period. Adage Capital Partners GP L.L.C. boosted its holdings in shares of Centessa Pharmaceuticals by 22.0% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 5,119,027 shares of the company's stock worth $85,744,000 after buying an additional 924,027 shares during the period. Franklin Resources Inc. boosted its position in shares of Centessa Pharmaceuticals by 0.3% in the fourth quarter. Franklin Resources Inc. now owns 2,308,546 shares of the company's stock valued at $38,668,000 after acquiring an additional 6,000 shares during the period. Foresite Capital Management VI LLC bought a new position in Centessa Pharmaceuticals during the fourth quarter valued at about $20,994,000. Finally, Affinity Asset Advisors LLC boosted its position in shares of Centessa Pharmaceuticals by 13.5% during the 4th quarter. Affinity Asset Advisors LLC now owns 1,095,924 shares of the company's stock valued at $18,357,000 after acquiring an additional 130,312 shares in the last quarter. 82.01% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on CNTA shares. Oppenheimer initiated coverage on Centessa Pharmaceuticals in a report on Thursday, May 8th. They set an "outperform" rating and a $6.00 price objective for the company. Piper Sandler started coverage on shares of Centessa Pharmaceuticals in a research note on Monday, March 31st. They set an "overweight" rating and a $38.00 price objective on the stock. Chardan Capital initiated coverage on shares of Centessa Pharmaceuticals in a research note on Thursday, May 8th. They issued a "buy" rating and a $30.00 target price for the company. Morgan Stanley restated an "overweight" rating and set a $27.00 price target on shares of Centessa Pharmaceuticals in a research report on Friday, March 7th. Finally, Guggenheim reiterated a "buy" rating and issued a $28.00 price objective on shares of Centessa Pharmaceuticals in a research report on Wednesday, March 26th. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Centessa Pharmaceuticals presently has a consensus rating of "Buy" and a consensus price target of $27.00.

Centessa Pharmaceuticals Trading Down 3.5%

NASDAQ:CNTA traded down $0.43 during mid-day trading on Wednesday, hitting $12.03. 220,954 shares of the company's stock were exchanged, compared to its average volume of 625,631. Centessa Pharmaceuticals plc has a fifty-two week low of $7.75 and a fifty-two week high of $19.09. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15. The firm has a market capitalization of $1.60 billion, a P/E ratio of -7.86 and a beta of 1.53. The company has a 50 day simple moving average of $13.70 and a 200-day simple moving average of $15.64.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last released its earnings results on Monday, May 12th. The company reported ($0.20) earnings per share for the quarter, beating analysts' consensus estimates of ($0.35) by $0.15. As a group, research analysts expect that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current year.

Insider Buying and Selling

In other news, General Counsel Iqbal J. Hussain sold 2,080 shares of Centessa Pharmaceuticals stock in a transaction dated Monday, April 28th. The shares were sold at an average price of $14.01, for a total value of $29,140.80. Following the completion of the transaction, the general counsel now owns 105,386 shares in the company, valued at $1,476,457.86. This trade represents a 1.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Saurabh Saha sold 55,000 shares of the company's stock in a transaction that occurred on Thursday, February 20th. The shares were sold at an average price of $15.93, for a total transaction of $876,150.00. Following the sale, the chief executive officer now owns 331,017 shares in the company, valued at $5,273,100.81. The trade was a 14.25% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 171,398 shares of company stock worth $2,697,422 in the last quarter. Insiders own 11.59% of the company's stock.

Centessa Pharmaceuticals Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.